Screener
Dianthus Therapeutics DNTH Equity Method Investments
Equity Method Investments at other companies
Other financials
Where this comes from
Reported directly by Dianthus Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:LongTermInvestments.
The source filing: Dianthus Therapeutics’s 10-Q, filed May 5, 2026.
- Filed
- May 5, 2026, 4:06 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001690585-26-000022
| Line item | March 31,2026 | December 31,2025 |
|---|---|---|
| Accounts receivable, net | 1,230 | 52 |
| Prepaid expenses and other current assets | 7,422 | 5,091 |
| Total current assets | 1,119,911 | 409,438 |
| Long-term investments | 113,868 | 110,135 |
| Property and equipment, net | 274 | 296 |
| Right-of-use operating lease assets | 1,293 | 1,337 |
| Other assets and restricted cash | 11,538 | 9,716 |
| Total assets | $1,246,884 | $530,922 |
Item 1. Condensed Consolidated Financial Statements (Unaudited)
FAQ
- What is Dianthus Therapeutics's equity method investments?
- Dianthus Therapeutics (DNTH) reported equity method investments of $113.87M in Q1 2026.
- How has Dianthus Therapeutics's equity method investments changed year-over-year?
- Dianthus Therapeutics's equity method investments increased by 66.7% year-over-year, from $68.31M to $113.87M.
- What does equity method investments mean?
- Investments in unconsolidated affiliates and joint ventures where the company has significant influence (typically 20-50% ownership), carried at proportional book value.
Ask your AI about Dianthus Therapeutics's equity method investments.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude